[
  {
    "ts": null,
    "headline": "Kidney Disease Trial Success Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)",
    "summary": "Vertex Pharmaceuticals recently reported positive clinical trial data for povetacicept in IgA nephropathy and primary membranous nephropathy, showing significant proteinuria reduction and stabilization of kidney function, and announced plans to begin rolling regulatory submissions for potential FDA accelerated approval in 2025. This breakthrough reinforces Vertex’s research capabilities in advancing therapies for kidney diseases, drawing strong interest from hedge funds and analysts alike as...",
    "url": "https://finnhub.io/api/news?id=9e698a75b55588a31b653e4e0a4dc6e2e79ec412826e2922f49473b363d6d0f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764299621,
      "headline": "Kidney Disease Trial Success Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)",
      "id": 137628326,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals recently reported positive clinical trial data for povetacicept in IgA nephropathy and primary membranous nephropathy, showing significant proteinuria reduction and stabilization of kidney function, and announced plans to begin rolling regulatory submissions for potential FDA accelerated approval in 2025. This breakthrough reinforces Vertex’s research capabilities in advancing therapies for kidney diseases, drawing strong interest from hedge funds and analysts alike as...",
      "url": "https://finnhub.io/api/news?id=9e698a75b55588a31b653e4e0a4dc6e2e79ec412826e2922f49473b363d6d0f6"
    }
  }
]